Study of JSKN033 for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called JSKN033 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 18 or older
- Has advanced or spreading solid tumor cancer that has not improved with standard treatments
- At least one tumor that can be measured on scans
- Able to care for yourself and do daily activities (performance status 0-1)
- Expected to live at least 3 more months
- No active brain metastases, uncontrolled fluid buildup, or recent major surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SSGJ-709 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
This trial tests a new drug, JSKN022, for people with advanced solid tumors that have stopped responding to standard treatments or are not eligible for them. The goal is to see if the drug is safe and effective.
This trial tests a new drug, JSKN021, for people with advanced solid tumors that have not responded to standard treatments, are not tolerated to them, or have no standard options. The goal is to see if the drug is safe and effective in treating these cancers.
This trial tests a new drug called JSKN027 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this drug is safe and if it can shrink tumors or slow their growth.
This trial tests a new drug, JSKN016HC, in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help shrink or control the tumor.
This trial tests a new drug, JSKN033, in people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be removed by surgery. It aims to see if the drug is safe and effective, and may be an option for those who have not improved with other treatments or have not yet had treatment.
Hear when a new Advanced Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.